New lipid lowering drugs help patients reduce LDL cholesterol supriya kashyap kashyap3 Aug 2016 12:49 PM ISTA recent analysis indicates that adding new therapies called anti-PCSK9 antibodies to other lipid-lowering treatments can help patients lower their...
No Evidence of Cognitive Issues When Evolocumab Added to Statin Therapy: ACC 2017 supriya kashyap kashyap29 March 2017 12:45 PM ISTWashington : There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other problems with...
These five tests better predict heart disease risk supriya kashyap kashyap5 April 2017 12:08 PM ISTFive simple medical tests together provide a broader and more accurate assessment of heart-disease risk than currently used methods, cardiologists at...
Subcutaneous injections twice a year - Inclisiran lowers LDL for up to one year (ORION 1) supriya kashyap kashyap6 Oct 2017 11:00 AM ISTBarcelona : Inclisiran lowers low-density lipoprotein (LDL; “bad”) cholesterol for up to one year in patients with high cardiovascular risk and...
When to add another drug to statin supriya kashyap kashyap9 Oct 2017 11:30 AM ISTDetermining when to add nonstatin therapy. A quantitative approachDespite optimal statin therapy, patients may remain at increased risk of...
Novel PCSK9 inhibitor, Inclisiran causes significant reduction of atherogenic lipoprotein Medha Baranwal Baranwal19 May 2018 8:25 PM ISTInclisiran, a small interfering RNA (siRNA) that inhibits proprotein convertase subtilisin kexin type 9 (PCSK9), produces significant and prolonged...
Best Dose of Evolocumab for stable LDL-Cholesterol reduction- Check it out Vinay Singh singh4 Jun 2018 8:25 PM ISTScott M. Wasserman at Thousand Oaks, CA, USA and associates conducted a study to ascertain the best dose of Evolocumab for stable LDL-Cholesterol...
Alirocumab reduces adverse CV events among heart attack survivors Medha Baranwal Baranwal11 Nov 2018 8:20 PM ISTAlirocumab, a cholesterol-lowering drug, was found to reduce the chance of additional heart problems or stroke among patients who had suffered a...
Alirocumab reduces risk of recurrent MI in ACS patients: ODYSSEY trial Medha Baranwal Baranwal2 Dec 2018 7:28 PM ISTAdministration of alirocumab in patients with a history of an acute coronary syndrome (ACS) and already receiving high-intensity statin therapy,...
PCSK9 inhibitor Evolocumab safely cuts LDL cholesterol across all stages of CKD Deepanjana Sarkar17 Jun 2019 8:20 PM ISTPCSK9 inhibitor, Evolocumab is clinically effective and safe for lowering Low-density lipoprotein cholesterol, LDL cholesterol levels across all...
Alirocumab-Statin Combo cuts risk of CV events in diabetics: ODYSSEY Trial Meghna Singhania30 Jun 2018 7:20 PM ISTAn analysis of ODYSSEY OUTCOMES trial indicates that Alirocumab, Statin Combo is more effective at reducing the risk of a cardiac event in diabetics...
